57 related articles for article (PubMed ID: 22507686)
1. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia.
Levine SZ; Leucht S
Eur Neuropsychopharmacol; 2012 Nov; 22(11):812-7. PubMed ID: 22507686
[TBL] [Abstract][Full Text] [Related]
2. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
Leucht S; Busch R; Hamann J; Kissling W; Kane JM
Biol Psychiatry; 2005 Jun; 57(12):1543-9. PubMed ID: 15953491
[TBL] [Abstract][Full Text] [Related]
3. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Levine SZ; Leucht S
Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
[TBL] [Abstract][Full Text] [Related]
4. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Citrome L
Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine.
Munro J; Matthiasson P; Osborne S; Travis M; Purcell S; Cobb AM; Launer M; Beer MD; Kerwin R
Acta Psychiatr Scand; 2004 Oct; 110(4):292-8. PubMed ID: 15352931
[TBL] [Abstract][Full Text] [Related]
6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
Psarros C; Theleritis CG; Paparrigopoulos TJ; Politis AM; Papadimitriou GN
Int J Geriatr Psychiatry; 2009 May; 24(5):518-22. PubMed ID: 19072747
[TBL] [Abstract][Full Text] [Related]
8. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
Blin O
Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
Kasper S
Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
[TBL] [Abstract][Full Text] [Related]
11. Attaining and sustaining remission of predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Jan; 143(1):60-4. PubMed ID: 23218563
[TBL] [Abstract][Full Text] [Related]
12. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
14. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
Levine SZ; Leucht S
Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Delcker A; Schoon ML; Oczkowski B; Gaertner HJ
Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
[TBL] [Abstract][Full Text] [Related]
17. Onset and persistence of antipsychotic response in patients with schizophrenia.
Glick ID; Bossie CA; Alphs L; Canuso CM
J Clin Psychopharmacol; 2009 Dec; 29(6):542-7. PubMed ID: 19910718
[TBL] [Abstract][Full Text] [Related]
18. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
19. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Apr; 145(1-3):125-7. PubMed ID: 23394742
[TBL] [Abstract][Full Text] [Related]
20. Signal detection and placebo response in schizophrenia: parallels with depression.
Mallinckrodt CH; Zhang L; Prucka WR; Millen BA
Psychopharmacol Bull; 2010; 43(1):53-72. PubMed ID: 20581800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]